Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12246290 | 1.00 | PTGS1 (0.42) | PTGS1PTGS2KMT2ATSHRTAS1R3 | |
| SCHEMBL4914536 | 0.81 | TSHR (0.46) | KMT2ATSHRMEN1NPC1RAB9A | |
| SCHEMBL2381923 | 0.81 | ALDH1A1 (0.55) | PTGS1PTGS2KMT2ATAS1R3TAS1R1 | |
| SCHEMBL12246309 | 0.81 | ALDH1A1 (0.55) | PTGS1PTGS2KMT2ATAS1R3TAS1R1 | |
| SCHEMBL12246287 | 0.79 | ALDH1A1 (0.54) | TSHRRAB9APOLBCYP2C9CYP2C19 | |
| SCHEMBL2381196 | 0.79 | ALDH1A1 (0.54) | TSHRRAB9APOLBCYP2C9CYP2C19 | |
| SCHEMBL828657 | 0.77 | TSHR (0.61) | KMT2ATSHRMEN1NPC1RAB9A | |
| SCHEMBL9421783 | 0.72 | SLC1A3 (0.56) | KMT2ATAS1R3TAS1R1MEN1MAPT | |
| SCHEMBL9053664 | 0.71 | TSHR (0.59) | PTGS1PTGS2KMT2ATSHRNPC1 | |
| SCHEMBL26706566 | 0.71 | TSHR (0.59) | PTGS1PTGS2KMT2ATSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017776-B2 | Methods for synthesis of acyloxyalkyl compounds | XENOPORT, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100041882-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL COMPOUNDS | XENOPORT, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7662987-B2 | Oxidation of 1-acyl alkyl compound under anhydrous condition | XENOPORT, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20050070715-A1 | Methods for synthesis of acyloxyalkyl compounds | ARBOR PHARMACEUTICALS, LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2005010011-A2 | METHODS OF SYNTHESIS OF ACYLOXYALKYL COMPOUNDS | XENOPORT, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070715-A1 | Methods for synthesis of acyloxyalkyl compounds | AADAC, CYP2D6, CYP3A7 | PTGS1 438/4885PTGS2 618/4885KMT2A 2674/4885 |
| US-20100041882-A1 | METHODS FOR SYNTHESIS OF ACYLOXYALKYL COMPOUNDS | AADAC, CYP2D6, CYP3A7 | PTGS1 438/4885PTGS2 618/4885KMT2A 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.